IMGN - ImmunoGen Inc.

IMGN valuation $655.69 million

Stock Price

7.63
Change: ↑ 1.43 (23.0645%)
Last Update: 2015-01-30T16:16:13-05:00
Shares Outstanding: 85,935,634
Industry: Biotechnology

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's antibody-drug conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own.

The first product approved with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned product candidates in clinical testing, with seven additional compounds in the clinic through the Company's partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi.

Stock Price Data

Open: 6.75 Previous Close: 6.20
High: 8.45 Low: 6.68
Bid: 7.52 Ask: 7.58

Bid Size: 400 Ask Size: 100
Raw Bid Size: 4 Raw Ask Size: 1
Trade Volume: 42246 Share Volume: 11540837
Last Trade Date: 2015-01-30 Last Trade Time: 16:00:00-05:00
Vwap: 7.77030287 EPS: -0.96

Fundamental Data

PE ratio: PB ratio: 11.058
Beta: 2.023056

52 Week High: 17.80 52 Week Low: 5.3432
52 Week High Vwap: 17.6159 52 Week Low Vwap: 5.6071
52 Week High Volume: 16592698 52 Week Low Volume: 304896
52 Week Avg Volume: 1121583
* Quotes delayed 15 minutes

Related Stocks

StockCompany namePrice
GILD Gilead Sciences Inc. 104.83
CELG Celgene Corporation 119.16
ARNA Arena Pharmaceuticals Inc. 4.31
MNKD MannKind Corporation 6.35
AMGN Amgen Inc 152.26
NVAX Novavax Inc. 7.81
BIIB Biogen Idec Inc. 389.16
NPSP NPS Pharmaceuticals Inc. 45.86
ARIA ARIAD Pharmaceuticals Inc. 6.45
PDLI PDL BioPharma Inc. 7.29